Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study

Background and Aim: Real world evidence on long term treatment of patients with familial hypercholesterolemia (FH) is important. We studied the effects of intensive lipid lowering medication (LLM) and optimized lifestyle in the study TTTFH–Treat To Target FH.Materials and Methods: Adults with a firs...

Full description

Bibliographic Details
Main Authors:	Kjell-Erik Arnesen, Ann Vinh Phung, Karoline Randsborg, Irene Mork, Marlene Thorvall, Gisle Langslet, Arne Svilaas, Cecilie Wium, Leiv Ose, Kjetil Retterstøl
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-03-01
Series:	Frontiers in Pharmacology
Subjects:	familial hypercholesterolemia ASCVD side effect TTTFH statin PCSK9-inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2020.560958/full

Similar Items

Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues
by: Gisle Langslet, et al.
Published: (2021-06-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
by: Alpo Vuorio, et al.
Published: (2021-05-01)

Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied
by: Leo Ungar, et al.
Published: (2018-08-01)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
by: Nagham N. Hindi, et al.
Published: (2021-08-01)

An investigation into statins, PCSK9 inhibitors, and other current cholesterol treatments
by: Kiley, Mark E.
Published: (2018)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
by: Chen CC, et al.
Published: (2018-12-01)

Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
by: Maria Mytilinaiou, et al.
Published: (2018-07-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

Family and polygenic hypercholesterolemia: similarities and differencies by long-term follow-up
by: B M Lipovetskiy, et al.
Published: (2009-03-01)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
by: Hayato Tada, et al.
Published: (2020-11-01)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01)

Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
by: Hines DM, et al.
Published: (2018-12-01)

Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
by: Pisciotta Livia, et al.
Published: (2012-09-01)

The efficacy and cost-effectiveness of evolocumab in the prevention of cardiovascular disease
by: Fahey, Kelly Marie
Published: (2019)

Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach
by: Alessandro Di Minno, et al.
Published: (2021-08-01)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
by: Dipti Athavale, et al.
Published: (2018-10-01)

Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation
by: Di Sun, et al.
Published: (2018-11-01)

Statin sensitive lipid-retinopathy in familial hypercholesterolemia
by: Aysha Salam, et al.
Published: (2013-01-01)

Preservation of Erectile Function by Statins in a Rat Model of Erectile Dysfunction Induced by Hypercholesterolemia
by: Bong Hee Park, et al.
Published: (2020-03-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA IN REAL OUTPATIENT PRACTICE (ACCORDING TO THE RECVASA REGISTRY)
by: A. I. Ershova, et al.
Published: (2015-09-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure
by: Khalid Al-Waili, et al.
Published: (2013-01-01)

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia
by: Hayato Tada, et al.
Published: (2021-04-01)

LDLR and ApoB are Major Genetic Causes of Autosomal Dominant Hypercholesterolemia in a Taiwanese Population
by: Kai-Chien Yang, et al.
Published: (2007-10-01)

Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State
by: Georgios Louloudis, et al.
Published: (2021-09-01)

The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype–Phenotype Correlations of the Disease
by: Amina Kamar, et al.
Published: (2021-01-01)

Evaluation Of Massive Parallel Sequencing As A Diagnostic Tool For Familial Hypercholesterolemia
by: Radoviča Ilze, et al.
Published: (2015-04-01)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
by: Jean-Philippe Drouin-Chartier, et al.
Published: (2017-06-01)

Correction of Hypercholesterolemia in Primary and Secondary Prevention of Cardiovascular Diseases: Features and Controversial Issues
by: N. M. Akhmedzhanov, et al.
Published: (2019-01-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Homozygous familial hypercholesterolemia with valvulopathy
by: Ashokan Nambiar, et al.
Published: (2019-01-01)

Prescription and adherence to statins of patients with coronary artery disease and hypercholesterolemia
by: Mansur Antonio P., et al.
Published: (2001-01-01)

Data on circulating leukocyte subpopulations and inflammatory proteins in children with familial hypercholesterolemia and healthy children
by: Jacob J. Christensen, et al.
Published: (2017-02-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

Proprotein Convertase Subtilisin/Kexin Type 9 Gene Variants in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis
by: Nang Hoang Pham, et al.
Published: (2021-02-01)

Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents
by: Tada H, et al.
Published: (2021-02-01)

Patients With <italic toggle="yes">LDLR</italic> and <italic toggle="yes">PCSK9</italic> Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
by: Takahito Doi, et al.
Published: (2021-02-01)

Letter to the Editor in response to “Response to Kovanen PT, et al. Letter to the Editor” for original article COVID-19 increases risk of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
by: Kelly D. Myers, et al.
Published: (2021-09-01)